Aristotle University Of Thessaloniki (AUTH)
Μελέτη των νευρολογικών και αιματολογικών επιπλοκών νοσηλευόμενων ασθενών που έχουν υποβληθεί σε κυτταρική θεραπεία
Abstract
dc:descriptionBackground: Cognitive dysfunction is a significant complication in recipients of chimeric antigen receptor T-cell (CAR-T) therapy. Nevertheless, prospective data on the use of simple, clinically available tools for the identification of cognitive dysfunction are lacking. Therefore, the present study aimed to prospectively and longitudinally evaluate cognitive function in patients undergoing CAR-T cell therapy, using simple and clinically available assessment tools, while investigating factors associated with the development of cognitive dysfunction. Methods: This was a single-center prospective cohort study that recruited consecutive adult patients with hematologic malignancies who received commercially available CAR-T cell products between May 2023 and November 2025 at the Transplant Unit of the Hematology Department of “George Papanikolaou” General Hospital in Thessaloniki. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) test and the Mini-Mental State Examination (MMSE) at baseline (before the administration of lymphodepleting chemotherapy – T1), 6 hours post infusion (T2), at 3 months (T3) and at 6 months (T4). Indicative of cognitive dysfunction were MoCA scores ≤ 25 and/ or MMSE scores ≤ 23. Results: Thirty-six patients enrolled in this study. Cytokine release syndrome was observed in 33/36 patients (91.7%) and immune effector cell-associated neurotoxicity syndrome (of any grade) in 23/36 patients (63.9%). At T1 (baseline), 12/36 patients (33.3%) exhibited cognitive dysfunction with the MoCA test. At T2 (following CAR-T products’ infusion), cognitive impairment was identified in 11/35 individuals (31.5%). Baseline (T1) cognitive dysfunction and older age were meaningfully associated with early post-administration cognitive impairment. During follow-up (T3 and T4), there were no significant overall cognitive status changes, as defined in the MoCA or MMSE tests. Notably, abstraction in MoCA and attention/calculation domains in MMSE displayed a time-dependent variation. Conclusion: This study demonstrated that simple, clinically accessible tools, such as the MoCA and MMSE tests, provide a reliable approach for longitudinal neurocognitive monitoring of CAR-T cell recipients in routine clinical practice. Furthermore, pre-infusion cognitive assessment may help identify patients at risk for early cognitive dysfunction following CAR-T cell therapy.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Strongyli, Evlampia
- Στρογγύλη, Ευλαμπία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62752